Back

argenx SE

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

  • Registration date 03 dec 2018 - 07:12
  • Statutory name argenx SE
  • Title argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia

Related downloads

201812030000000001_argenx.pdf

Date last update: 18 July 2019

Share information

Share on: Share this